Global Statistics Representing Viral Vector Manufacturing Market Scenario
Cytogenetic method, biochemical method, physiological technique, molecular technique, and immunological technique are used to transfer genetic materials to different organisms. Gene transfer is one of the highly preferred modes of transfer and is used across the fields of medicine, agriculture biotechnology, and plant biotechnology. According to Cancer Research, U.K. Non-Hodgkin lymphoma is the sixth largest cancer in the U.K., and its prevalence is the highest among the people aged 80–84.
Increasing prevalence of retinal eye diseases and targeted diseases, and rising research and development activities in drug designing are the major factors driving the market growth. Gene therapy mainly targets hyperlipidaemias, and more than 12% of adults aged 20 or above are suffering from hyperlipidaemias in the U.S.
Viral vector manufacturing market was valued at USD 254.54 million in 2018, at a CAGR of 9.2% during the forecast period 2019-2026.
Global viral vector manufacturing market is segmented by type, disease, application, end-user, and regions
Based on type, the global viral vector manufacturing market is segmented into Retrovirus Vectors, Adenovirus Vectors, and Adeno-Associated Viral Vectors. Adeno-associated viral vector segment is expected to hold a major market share as the vector can transfect both dividing and non-dividing cells and lacks pathogenicity. Adeno-Associated viral vectors can be studied on both human and animal cell models. Luxturna drug is am Adeno-Associated based viral drug, which helps cure retinal defects. According to the European Society of Retina Specialists, the number of retinal vein occlusion would rise to 1 million by 2050.
Based on the disease, the viral vector manufacturing market is segmented into cancer, genetic disorders, and infectious disease. Cancer disease segment is expected to dominate the viral vector manufacturing market following the increasing prevalence of cancer patients around the world.
By application, the market is segmented into gene therapy and vaccinology. Gene therapy segment is expected to lead the segment during the forecast period 2019–2026.
On the basis of end-user, the viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies, research centers, and others.
Pharmaceutical and biopharmaceutical companies segment is leading the market as a result of ongoing research and development in drug designing. Apart from this, the U.S FDA granted approval for the drugs of cancer, cardiovascular disease, and genetic disease.
Geographically, the viral vector manufacturing market is segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is expected to dominate the viral vector manufacturing market during the forecast period as a result of increasing research and development in the region. As per the American Cancer Society, over 6 per 10 people are diagnosed with prostate cancer, and this number has increased to 2.9 million. Moreover, Adenovirus Vectors are used in cancer gene therapy, and vaccines to express foreign antigens. Oncolytic viruses are genetically transfected with adenovirus viral vector to destroy the cancer cells. ‘Imlygic’ (talimogene laherparepvec) was the first-ever oncolytic virus designed by Amgen Inc for treating Metastatic melanoma, and its patent will expire in January 2021. According to the American cancer society, 96,480 new melanoma cases were reported, and Imlygic drug is the only treatment available for melanoma in the U.S.
Europe is holding the second largest market share in the viral vector manufacturing market. European countries such as Germany, the U.K, and France are highly engaged in research and development activities for developing new drugs and life science. Asia Pacific market is likely to grow at the highest CAGR during the forecast period. In Asia, the prevalence of chronic diseases like diabetes and cancer is growing at a significant pace. Gene therapy or stem cell therapy is boon for these diseases. LAMEA is an emerging region in the global viral vector manufacturing market due to poor healthcare infrastructure and low research and development activities in the Middle East and Africa.
Some of the key players in the global viral vector manufacturing market are Merck kGA (Germany), Lonza (Switzerland), BD (U.S.), Fujifilm Diosynth biotechnologies USA Inc (U.S.), Brammer Bio (U.S.), Cell Therapy Catapult Limited (U.K.), Waisman Biomanufacturing (U.S.), GENEZEN LABORATORIES (U.S.), Yposkesi, Inc. (France), and REGENXBIO Inc (U.S)
Our Report Covers
Viral Vector Manufacturing Market Segmentation
By End User
o North America
o South America
o Western Europe
o Eastern Europe
o South Korea
o Rest of Asia Pacific
The Middle East & Africa
o The Middle East